Skip to content

Clinical Study for Non-spontaneous Membranous Nephropathy from the Treatment of Shaoyin-Taiyin Syndrome Based on Liujing Syndrome Differentiation

Clinical Study for Non-spontaneous Membranous Nephropathy from the Treatment of Shaoyin-Taiyin Syndrome Based on Liujing Syndrome Differentiation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021485
Enrollment
Unknown
Registered
2019-02-23
Start date
2019-02-25
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous Nephropathy

Interventions

Treatment:Oral Mahuang Fuzi Soup and Shenzhuo Soup

Sponsors

Beijing Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 Conforms to the IMN diagnostic criteria: The pathological light microscopy or electron microscopy has been used for the diagnosis of idiopathic membranous nephropathy (Wang Haiyan's "Nephrology" 3rd edition) or atypical membranous nephropathy. 2 Compliant with the diagnostic criteria of Chinese medicine Shaoyin Taiyin syndrome: (in combination with Feng Shilun's editor-edited "Interpretation of Zhang Zhongjing Medicine" standard): Main card: aversion to cold, cold hands and feet, back pain, edema, bloating, loose stools or dry stool, The tongue is tender, the moss is thin or watery, and the pulse is heavy. Second certificate: fatigue, shortness of breath, lazy words, spontaneous sweating, little urination, nocturia and so on. With the above three main certificates, sub-certificate 2 two, you can determine the Shaoyin Taiyin syndrome. 3 CKD1-3 patients (GFR>30ml/min).

Exclusion criteria

Exclusion criteria: 1 Progressive membranous nephropathy (degraded renal function; renal biopsy see necrotizing capillary vasculitis and >50% large crescent formation), accompanied by other kidney diseases such as IgA nephropathy, diabetic nephropathy; 2 Confirmed by hepatitis B, systemic lupus erythematosus, tumor, drug damage and other factors secondary and need to actively treat the primary disease, such as active hepatitis B and persistent liver function test transaminase abnormalities; or anti-nuclear antibodies, double Abnormal strand DNA, ANCA or other indicators of immune disease; 3 Patients with acute central nervous system diseases, severe gastrointestinal diseases, history of HIV infection, history of psychosis, history of malignant tumors; 4 Patients with other organs with serious diseases and dysfunctions, and with life-threatening complications such as severe infection; 5 Pregnant or lactating women; 6 Receiving other clinical trial researchers. Patients with any of the above conditions must be excluded from the study.

Design outcomes

Primary

MeasureTime frame
24-hour urine protein;Blood albumin;

Secondary

MeasureTime frame
TCM syndrome scores;Anti-PLA2 Antibody;Total Cholesterol;Triglyceride;Kidney Function Test;

Countries

People Republic of China

Contacts

Public ContactLiu Baoli

Beijing Hospital of TCM

polyliu2000@sina.com+86 18901051212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026